valu usd unless otherwis note
slow trim ep
view trim estim cardin health
believ continu oper issu medic busi weigh
result price assumpt brand drug busi could prove
trim estim challeng persist reduc
revenu ep estim cardin follow recent compani
present discuss suspect brand drug price increas
could come expect given challeng medic
segment compani like reinvest synergi achiev
improv oper perform reduc estim
note estim consensu
current guidanc rang impli
manag team recent indic guidanc rang assum
manufactur take mid singl digit price increas januari
figur choos take conserv view cardin indic
juli price increas weaker expect depend
pend hh rebate/pr rule omb fear januari increas
could tepid well side gener inflat continu run
mid-to-high singl digit deflat also like weigh result
model drug segment op reduct
low end compani guidanc
medical/surg save like reinvest given challeng
compani medic segment expect synergi
deliv reinvest back busi improv
oper perform cordi acquisit cardin
see lower gross margin previous expect unit
manufactur scale diminish sg expens run
higher rate compani tri correct inventori issu compani
hope remedi issu exit
maintain sector perform maintain sector perform rate
share modestli increas pt time earn get
push revis price target
reflect ep estim
price prior trade day market close estimate unless otherwis note
cardin health one three larg drug wholesal
unit state believ share like
multipl range-bound investor get visibl
gener drug price bottom oper
earn growth resum compani
pressur last month gener drug price
deflat increas wholesal competit higher-margin
independ custom slowdown brand drug price
increas weigh result expect
backdrop improv next twelv month end
believ investor expect estim
compani core drug distribut segment bottom
could continu disappoint
estim cardin gener
profit core us drug distribut busi sale
gener drug past two year cardin seen
price gener drug deflat high singl digit mid-teen
percentag rate profit dollar contribut fall
slightli lower rate cardin grow profit gener
drug need volum growth new introduct off-set
impact drug price deflat believ
possibl gener deflat continu high singl digit
pace higher thu current environ persist
upsid risk rate includ stabil drug
price environ could caus earn estim
stabil like drive multipl expans close
outperform expect drive posit earn
gener market potenti client loss
wholesal sell side price compress
larger pharmaci custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount year averag forward trade multipl
share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep upsid scenario
ep better ep growth could driven
success medic devic strategi increas volum across
brand gener drug de-lever balanc sheet
level gener price deflat forward
multipl repres high end normal trade
rang drug wholes space multipl
like get neg share
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower expect ep could
driven hiccup implement medic devic
strategi wors expect price environ lower
expect brand gener volum forward
multipl like get posit share
exhibit ep estim chang street ep estim
exhibit put take
assumpt chang highlight tabl
ep estim quarter current prior put put takestailwindspharma organ volum growth specialty organ revenu organ growthic margin assum reinvest recoveri acquisit full year manufactur modest tailwind beforeheadwindscust win loss agreement end june gener continu challeng herebrand drug price brand drug price increas low endinvest spend custom surg increas tax rate reduct share repurchasesimpli guid move chang ep care technolog distribut
price target share equal ep estim use
multipl reflect slight discount year averag forward trade multipl
share reflect challeng medic segment price target support
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
cah medic surgic busi could also outperform expect drive posit
earn surpris downsid risk includ acceler drug price deterior
gener market potenti client loss wholesal sell side
price compress larger pharmaci custom gpo
healthcar servic product compani offer solut health
system pharmaci healthcar provid compani oper
medic segment busi distributor
brand gener drug specialti drug over-the-counter healthcar product
segment also provid specialti pharmaci servic china joint ventur
call red oak sourc sourc gener pharmaceut
medic busi distributor nation brand medic surgic
laboratori product healthcar provid patient home segment addit
provid profession servic healthcar provid
good sold
revenu
impair charg net
litig credit net
revenu
adj profit tax
profit tax
weight average number share
